| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
TSE:EPRX
Eupraxia Pharmaceuticals
|
Jun 26, 2026 | BUY |
Strong Buy
+150.2% avg upside
9 analysts
|
$24.14
164.59% Upside
|
· |
|
DFTX
Definium Therapeutics
|
Jun 22, 2026 | BUY |
Strong Buy
-5.9% avg upside
20 analysts
|
$60.00
33.88% Upside
|
· |
|
CHRS
Coherus Biosciences
|
Jun 22, 2026 | BUY |
Buy
+746.9% avg upside
18 analysts
|
$10.00
575.73% Upside
|
· |
|
ZNTL
Zentalis Pharmaceuticals
|
Jun 15, 2026 | BUY |
Buy
+277.0% avg upside
16 analysts
|
$9.00
137.44% Upside
|
· |
|
APRE
Aprea Therapeutics
|
Jun 15, 2026 | BUY |
Buy
+2794.9% avg upside
7 analysts
|
$5.00
533.09% Upside
|
· |
|
INCY
Incyte
|
Jun 08, 2026 | HOLD |
Buy
-7.1% avg upside
47 analysts
|
$107.00
0.44% Downside
|
+7.8% |
|
PRAX
Praxis Precision Medicines
|
Jun 02, 2026 | BUY |
Strong Buy
+66.2% avg upside
24 analysts
|
$650.00
98.19% Upside
|
+27.0% |
|
RVMD
Revolution Medicines
|
Jun 01, 2026 | BUY |
Strong Buy
-17.2% avg upside
32 analysts
|
$195.00
9.52% Upside
|
+3.7% |
|
ANL
Adlai Nortye Ltd. Sponsored ADR
|
May 28, 2026 | BUY |
Strong Buy
+109.7% avg upside
6 analysts
|
$32.00
214.94% Upside
|
· |
|
DNLI
Denali Therapeutics
|
May 11, 2026 | BUY |
Strong Buy
+50.7% avg upside
24 analysts
|
$40.00
61.69% Upside
|
+25.9% |
|
NKTR
Nektar Therapeutics
|
May 08, 2026 | BUY |
Buy
+13.2% avg upside
25 analysts
|
$140.00
125.79% Upside
|
-17.3% |
|
NBIX
Neurocrine
|
May 06, 2026 | BUY |
Strong Buy
+4.0% avg upside
37 analysts
|
$230.00
40.05% Upside
|
+7.7% |
|
VRTX
Vertex Pharmaceuticals
|
May 05, 2026 | BUY |
Strong Buy
-8.4% avg upside
61 analysts
|
$600.00
24.99% Upside
|
+10.0% |
|
SGMT
Sagimet Biosciences, Inc. Class A
|
May 01, 2026 | BUY |
Strong Buy
+305.0% avg upside
15 analysts
|
$33.00
381.01% Upside
|
-9.3% |
|
EXEL
Exelixis
|
Apr 27, 2026 | HOLD |
Buy
-22.1% avg upside
33 analysts
|
— | +15.0% |
|
PASG
Passage Bio
|
Apr 27, 2026 | HOLD |
Buy
+314.8% avg upside
14 analysts
|
— | -10.3% |
|
BNTX
BioNTech SE
|
Apr 27, 2026 | HOLD |
Strong Buy
+51.8% avg upside
26 analysts
|
— | -10.9% |
|
CMPS
COMPASS Pathways
|
Apr 24, 2026 | BUY |
Strong Buy
+51.7% avg upside
18 analysts
|
$20.00
47.24% Upside
|
+24.6% |
|
HRMY
Harmony Biosciences Holdings
|
Apr 22, 2026 | BUY |
Strong Buy
+36.1% avg upside
13 analysts
|
$72.00
110.93% Upside
|
-5.9% |
|
MRNA
Moderna
|
Apr 20, 2026 | HOLD |
Hold
+14.5% avg upside
38 analysts
|
— | +10.7% |
|
ATAI
Atai Beckley N.V.
|
Apr 05, 2026 | BUY |
Strong Buy
+199.1% avg upside
16 analysts
|
$16.00
249.33% Upside
|
+4.2% |
|
TVRD
Tvardi Therapeutics
|
Apr 02, 2026 | BUY |
Buy
+655.0% avg upside
23 analysts
|
$10.00
323.72% Upside
|
+9.3% |
|
BIIB
Biogen
|
Apr 01, 2026 | BUY |
Buy
+21.6% avg upside
51 analysts
|
$275.00
36.19% Upside
|
+8.7% |
|
BCYC
Bicycle Therapeutics
|
Mar 18, 2026 | BUY |
Strong Buy
+507.3% avg upside
20 analysts
|
$36.00
797.72% Upside
|
-7.2% |
|
SKYE
Skye Bioscience
|
Mar 11, 2026 | BUY |
Strong Buy
+1381.0% avg upside
9 analysts
|
$10.00
1311.54% Upside
|
+12.3% |
|
QTTB
Q32 Bio
|
Mar 11, 2026 | BUY |
Buy
+350.7% avg upside
24 analysts
|
$20.00
67.37% Upside
|
-20.4% |
|
IMRX
Immuneering
|
Mar 09, 2026 | BUY |
Strong Buy
+292.7% avg upside
10 analysts
|
$30.00
562.32% Upside
|
-8.2% |
|
BIOA
BioAge Labs, Inc.
|
Feb 25, 2026 | BUY |
Strong Buy
+117.9% avg upside
9 analysts
|
$60.00
165.24% Upside
|
-20.2% |
|
MDGL
Madrigal Pharmaceuticals
|
Feb 09, 2026 | BUY |
Strong Buy
-7.1% avg upside
31 analysts
|
$650.00
26.57% Upside
|
+4.7% |
|
AMGN
Amgen
|
Jan 29, 2026 | BUY |
Buy
-15.4% avg upside
57 analysts
|
$400.00
13.35% Upside
|
+2.7% |
|
OVID
Ovid Therapeutics
|
Nov 13, 2025 | BUY |
Strong Buy
+96.1% avg upside
17 analysts
|
$7.00
189.26% Upside
|
+119.2% |
|
IBIO
Ibio
|
Nov 13, 2025 | BUY |
Strong Buy
+263.3% avg upside
11 analysts
|
$6.00
277.41% Upside
|
+27.8% |
|
CNTA
Centessa Pharmaceuticals
|
Nov 13, 2025 | BUY |
Buy
-21.1% avg upside
19 analysts
|
$40.00
1.26% Downside
|
+56.0% |
|
NTLA
Intellia Therapeutics
|
Nov 07, 2025 | BUY |
Buy
+148.2% avg upside
37 analysts
|
$27.00
68.52% Upside
|
+27.2% |
|
IONS
Ionis Pharmaceuticals
|
Oct 27, 2025 | BUY |
Strong Buy
+8.0% avg upside
43 analysts
|
$90.00
14.79% Upside
|
+8.1% |
|
GANX
Gain Therapeutics
|
Oct 07, 2025 | BUY |
Strong Buy
+355.5% avg upside
9 analysts
|
$8.00
365.17% Upside
|
-11.4% |
|
VKTX
Viking Therapeutics
|
Oct 07, 2025 | BUY |
Strong Buy
+95.2% avg upside
31 analysts
|
$100.00
170.35% Upside
|
-6.0% |
|
VYGR
Voyager Therapeutics
|
Oct 02, 2025 | BUY |
Strong Buy
+298.9% avg upside
23 analysts
|
$18.00
407.11% Upside
|
-25.9% |
|
JSPR
Jasper Therapeutics
|
Jun 16, 2025 | BUY |
Strong Buy
+6416.9% avg upside
17 analysts
|
$65.00
14579.25% Upside
|
-92.0% |
|
PRTA
Prothena
|
Jun 16, 2025 | HOLD |
Buy
+151.3% avg upside
14 analysts
|
— | +46.5% |
|
STRO
Sutro Biopharma
|
Mar 14, 2025 | HOLD |
Strong Buy
+30.0% avg upside
20 analysts
|
— | +184.9% |
|
GILD
Gilead Sciences
|
Feb 12, 2025 | BUY |
Strong Buy
-5.1% avg upside
66 analysts
|
$115.00
7.08% Downside
|
+51.0% |
|
ENTA
Enanta Pharmaceuticals
|
Dec 10, 2024 | HOLD |
Buy
+143.6% avg upside
17 analysts
|
$14.00
4.07% Upside
|
+66.3% |
|
ACAD
ACADIA Pharmaceuticals
|
Nov 08, 2024 | HOLD |
Strong Buy
+51.9% avg upside
42 analysts
|
$17.00
28.36% Downside
|
+27.8% |
|
CRSP
Crispr Therapeutics AG
|
Nov 06, 2024 | BUY |
Buy
+39.2% avg upside
41 analysts
|
$95.00
75.96% Upside
|
+11.6% |
|
EDIT
Editas Medicine
|
Nov 05, 2024 | HOLD |
Buy
+396.7% avg upside
33 analysts
|
— | -10.9% |
|
CGTX
Cognition Therapeutics
|
Nov 04, 2024 | BUY |
Strong Buy
+425.9% avg upside
9 analysts
|
$9.00
696.49% Upside
|
+223.1% |
|
DMRA
Damora Therapeutics
|
Oct 17, 2024 | BUY |
Strong Buy
+20.5% avg upside
19 analysts
|
$10.00
55.61% Downside
|
· |
|
INO
Inovio Pharmaceuticals
|
Aug 12, 2024 | BUY |
Strong Buy
+830.9% avg upside
19 analysts
|
$33.00
2955.54% Upside
|
-82.1% |
|
BIVI
BioVie
|
Feb 26, 2024 | HOLD |
Buy
+836.3% avg upside
6 analysts
|
— | -88.4% |
|
KRRO
Korro Bio
|
Feb 14, 2023 | HOLD |
Strong Buy
+118.7% avg upside
19 analysts
|
— | +46.7% |
|
RLMD
Relmada Therapeutics
|
Nov 14, 2022 | BUY |
Buy
+114.2% avg upside
15 analysts
|
$7.00
8.61% Upside
|
-52.3% |
|
KURA
Kura Oncology
|
Aug 14, 2020 | HOLD |
Strong Buy
+148.6% avg upside
26 analysts
|
— | -21.4% |
|
TPST
Tempest Therapeutics
|
Jun 12, 2020 | HOLD |
Buy
+1974.8% avg upside
18 analysts
|
— | -32.2% |
|
IMVIF
IMV
|
May 08, 2020 | HOLD |
Buy
+2407232524.9% avg upside
7 analysts
|
— | · |
|
TXMD
TherapeuticsMD
|
Aug 22, 2019 | BUY |
Buy
+205.2% avg upside
8 analysts
|
$9.00
343.33% Upside
|
-44.6% |
|
MDWD
Mediwound
|
Aug 14, 2019 | BUY |
Strong Buy
+46.7% avg upside
13 analysts
|
$7.00
52.00% Downside
|
+16.9% |
|
INDP
Indaptus Therapeutics
|
Jul 22, 2019 | HOLD |
Buy
+2745.6% avg upside
6 analysts
|
— | -2.9% |
|
SPRO
Spero Therapeutics
|
Mar 24, 2019 | BUY |
Buy
+574.3% avg upside
12 analysts
|
— | -49.8% |
|
VTGN
VistaGen Therapeutics
|
Mar 15, 2019 | HOLD |
Hold
+321.6% avg upside
8 analysts
|
— | -68.5% |
|
TARA
Protara Therapeutics
|
Dec 08, 2017 | HOLD |
Strong Buy
+1140.1% avg upside
21 analysts
|
— | -7.9% |
|
ARCT
Arcturus Therapeutics
|
Jan 20, 2017 | HOLD |
Buy
+323.8% avg upside
35 analysts
|
— | +32.0% |
|
TNXP
Tonix Pharma
|
Dec 30, 2016 | HOLD |
Strong Buy
+126.4% avg upside
8 analysts
|
— | -26.6% |
|
MNKD
MannKind
|
Mar 30, 2016 | SELL |
Buy
+80.0% avg upside
22 analysts
|
$0.25
93.60% Downside
|
+82.3% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.